Abstract Purpose: CPX-1 is a novel, liposome-encapsulated formulation of irinotecan and floxuridine designed to prolong in vitro optimized synergistic molar ratios of both drugs postinfusion. This open-label, single-arm, dose-escalating phase I study was designed to determine the maximum tolerated dose and pharmacokinetics of CPX-1in patients with advanced solid tumors. Experimental Design: Patients received CPX-1 at 30, 60, 100, 150, 210, or 270 units/m 2 (1 unit = 1 mg irinotecan + 0.36 mg floxuridine) infused over 90 minutes every 14 days in 28-day cycles. Pharmacokinetic samples were collected on days 1and 15 of cycle 1. Results: Thirty-three patients were enrolled, treated, and evaluated for safety; 30 patients were evaluated for response. A 1:1plasma irinotecan to floxuridine molar ratio was maintained for 8 to 12 hours. Grade 3/4 toxicities included diarrhea (24.2%), neutropenia (12.1%), and hypokalemia (12.1%); 1 patient (270 units/m 2
The backbone of systemic therapy for cancer is combination chemotherapy. Historically, oncologists have assumed that greater antitumor activity can be achieved by administering combinations of active cytotoxic agents at maximally tolerated doses rather than using single-agent strategies (1, 2) . However, in vitro studies of chemotherapy doublets with established clinical activity have suggested that efficacy may depend on the molar ratio of the two agents (3 -7) . Certain ratios of drug combinations can be synergistic, whereas other ratios of the same agents can be additive or antagonistic. This observation has important implications for maximizing the effectiveness of combination chemotherapy and suggests that improved efficacy may be achieved if the molar ratios that tumor cells are exposed to can be controlled in vivo. Because different anticancer drugs are pharmacokinetically dissimilar, conventional aqueous drug formulations will not allow either the maintenance or the delivery of optimal molar ratios to the tumor, resulting in exposure to suboptimal or antagonistic ratios (8) . This problem can be overcome by encapsulating drug combinations within nanoscale carriers capable of maintaining synergistic drug ratios systemically through pharmacokinetic control. This approach has been shown to markedly increase the therapeutic index of several cancer drug combinations in preclinical studies (4, 5, 7) .
Since the approval of irinotecan in 1996, the combination of i.v. irinotecan plus 5-fluorouracil (5-FU) and leucovorin has become a standard chemotherapy for first-and secondline treatments of metastatic colorectal cancer either alone or in combination with targeted biological agents such as bevacizumab and epidermal growth factor receptor inhibitors (9 -15) . In these treatment regimens, irinotecan and 5-FU are both administered i.v. with irinotecan injected as a short (30-120 minutes) infusion and 5-FU most frequently given as a bolus injection plus a 22-hour infusion the same day as irinotecan. In view of our in vitro observations of drug ratio -dependent synergy for irinotecan and fluorinated pyrimidine, we developed a liposome-based formulation coencapsulating irinotecan and floxuridine to assess whether controlling the ratio of these two drugs in vivo could improve therapeutic activity (5, 7) . Floxuridine was used rather than 5-FU due to its compatibility with drug delivery technology as well as the fact that i.v. 5-FU and floxuridine have been shown to exhibit equivalent clinical activity (16, 17) .
In preclinical studies, irinotecan and floxuridine exhibited the highest degree of in vitro synergy when molar ratios were between 1:1 and 1:5 (5). Consequently, a 1:1 molar ratio was chosen as the optimal ratio on the basis of demonstrated synergy across the highest proportion of cell lines studied. CPX-1 (Celator Pharmaceuticals, Inc.) was developed by fixing the molar ratio of irinotecan and floxuridine at 1:1 within a liposomal carrier that was able to control the plasma concentrations of both drugs such that the 1:1 molar ratio was maintained for up to 24 hours. In vivo tests of CPX-1 in a variety of human xenograft and allogeneic solid tumor models showed consistently superior antitumor efficacy when compared with both conventional combinations of irinotecan and floxuridine at the maximum tolerated dose, as well as liposomal formulations of the individual drugs administered at the maximum tolerated dose (5, 7). Furthermore, the degree of antitumor activity observed for CPX-1 was consistent with in vivo synergy when compared with the individual liposomal agents. A striking observation was that liposome delivery of an irinotecan to floxuridine molar ratio shown to be antagonistic in vitro provided less antitumor activity than liposomal irinotecan alone, despite administration of the same dose of irinotecan and the addition of fluoropyrimidine, an agent known to be active in that in vivo model (5) .
CPX-1 is being developed with the hypothesis that it will be more efficacious than conventional irinotecan and fluoropyrimidine in the treatment of sensitive malignancies. Administration of chemotherapy combinations within drug carriers to achieve synergistic molar ratios at the site of drug action has not, to date, been studied in the clinic as a means of improving the efficacy of antitumor treatment. The objectives of this phase I study were to determine the maximum tolerated dose of CPX-1 for use in future studies and to assess the toxicity profile at the maximum tolerated dose. Data were collected to determine the duration of maintenance of the intended 1:1 molar ratio and the bioavailability of irinotecan and floxuridine. Early observations of CPX-1 efficacy are also presented.
Materials and Methods
The study was conducted between January 2005 and June 2007. Both clinical sites obtained approval from their respective Research Ethics Boards and all patients provided written informed consent.
Patients. Eligible patients provided written informed consent; were z18 years of age; and had confirmed histologic or cytologic advanced solid tumor not curable by conventional surgery, radiotherapy, or chemotherapy. Enrollment criteria included Eastern Cooperative Oncology Group performance status of V2, absolute neutrophil count >1.5 Â 10 9 /L, platelet count >100 Â 10 9 /L, serum creatine <1.5 times the upper limit of normal, aspartate transaminase and alanine transaminase <3 times the upper limit of normal (<5 times the upper limit of normal if caused by liver metastasis), serum total bilirubin <1.25 times the upper limit of normal, and an international normalized ratio <1.5. Exclusion criteria included any serious medical condition, laboratory abnormality, or psychiatric illness that prevented patients from providing informed consent; treatment with chemotherapy, radiation therapy, or other investigational anticancer therapeutic drugs within 4 wk before study entry (6 wk for prior nitrosoureas or mitomycin chemotherapy); the presence of primary brain tumors, lymphoma, or other hematologic malignancies; the presence of brain metastases that were not stable for z6 mo; pregnant or lactating females; the presence of clinically significant cardiac disease (New York Heart Association Class III or IV); severe, debilitating pulmonary disease; the presence of an infection that required continuing i.v. antibiotic treatment; severe or active enteropathy, or recent onset of diarrhea (defined as an excess of two to three stools above the normal daily rate within 4 wk before study entry); a history of Wilson's disease or other copper-related disorder (due to the copper used in the formulation of CPX-1); and hypersensitivity to irinotecan, floxuridine, or liposomal products.
All laboratory variables were evaluated before treatment and 4 wk posttreatment. Hematology exams were done twice weekly during cycle 1 and once weekly thereafter; biochemistry analyses were done weekly; coagulation studies were done on day 1 of each cycle. Because CPX-1 contains copper, serum copper levels were measured weekly during cycle 1 and on day 1 of each cycle thereafter.
Premedication. Antiemetics and antidiarrheal agents (loperamide) were administered at onset of nausea and vomiting or diarrhea during cycle 1 and could be used prophylactically for subsequent treatment cycles. For hypersensitivity or infusion-related reactions, treatment was stopped and potentially reinitiated (depending on the severity of the reaction), with or without i.v. diphenhydramine and dexamethasone.
Drug formulation and dosing regimen. CPX-1 is a liposomal formulation of irinotecan HCl trihydrate and floxuridine held in a fixed 1:1 molar ratio. The CPX-1 liposome membrane is composed of distearylphosphatidylcholine, distearylphosphatidylglycerol, and cholesterol in a 7:2:1 molar ratio.
In dogs given four weekly i.v. doses, the toxic low dose of CPX-1 was irinotecan 5 mg/kg plus floxuridine 1.8 mg/kg; twice this CPX-1 dose was not lethal (data on file). Based on this toxicology information, the starting dose of CPX-1 was irinotecan 30 mg/m Although many dosing regimens have been evaluated for irinotecan, the most common are once every 3 wk or once weekly dosing (10 -12) . It is commonly assumed that exposure time rather than concentration is more important for response to cell cycle -specific drugs; thus, a weekly schedule might be better than an every 3 weeks schedule. However, the half-lives of irinotecan and SN-38 in dogs receiving CPX-1 were 3 to 6 times longer than historical data for irinotecan in dogs (18) ; thus, a decision was made to use an every 2 weeks schedule.
Treatment cycles were repeated once every 28 d in the absence of unacceptable toxicity or evidence of disease progression. Patients with stable disease or partial response continued therapy until disease
Translational Relevance
This study represents the first step in the clinical testing of a novel concept in combination chemotherapy for cancer. Ratiometric dosing is an innovation that could enhance many combinations of drugs currently used to treat various cancers and may affect the development of future combinations. Based on sound theory and experimental data, this phase I study confirms the safety and efficacy of the first ratiometrically designed drug combination tested. /L) associated with bleeding. Grade 3 alanine transaminase or aspartate transaminase toxicity did not constitute dose-limiting toxicity in subjects with liver metastases starting treatment with alanine transaminase or aspartate transaminase 3 to 5 times the upper limit of normal. Treatment was delayed or reduced for hematologic and other toxicities that were possibly, probably, or definitely related to protocol therapy. Toxicities were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0.
Subsequent cohorts began the next dose level when dose-limiting toxicities were confirmed absent after 28 d of follow-up. If one patient at a given dose level experienced dose-limiting toxicities, additional patients were treated at the same dose level up to a total of six patients. Dose escalation continued only if no more than one of the six patients experienced dose-limiting toxicities. If two or more patients experienced dose-limiting toxicities at a given dose level, further dose escalation was discontinued. Additional patients were then added to the next lower dose level until a total of six patients were treated. If no more than one of the six patients experienced dose-limiting toxicities at this dose level, it was declared the maximum tolerated dose. Additional patients were treated at the maximum tolerated dose to confirm safety and to explore preliminary evidence of antitumor activity (extension cohort). Subjects with prior irinotecan treatment were allowed entry if there was no evidence of primary irinotecan resistance and if their last irinotecan dose was administered >12 mo before the initiation of CPX-1 treatment.
Patients who received at least one cycle of CPX-1 treatment and had at least one measurable lesion were considered evaluable for response; patients who did not complete one cycle of CPX-1 treatment because they had early disease progression (i.e., the progression of target or nonmeasurable lesions or the appearance of new lesions) were considered evaluable for progression-free survival. Disease status was assessed using Response Evaluation Criteria in Solid Tumors guidelines (20) . Response duration was measured as the time between the first documentation of complete remission or partial remission and the onset of progressive disease. Stable disease duration was measured from the start of therapy until the onset of progressive disease.
Pharmacokinetics. Blood samples for pharmacokinetic analyses were collected before CPX-1 infusion and at 45 and 85 min and at 2, 4, 6, and 8 h after the initiation of CPX-1 infusion on days 1 and 15; additional samples were collected at 24, 48, 72, 96, and 168 h after the initiation of infusion on day 1. Plasma was analyzed for total irinotecan (we did not distinguish free from encapsulated nor the lactone form from the carboxylic acid), 7-ethyl-10-hydroxy-camptothecin (SN-38), total floxuridine (free plus encapsulated), and 5-FU using validated, specific high-performance liquid chromatographic mass spectrometric methods with lower limits of quantitation of 240, 1, 50, and 10 ng/mL, respectively. Both intraday and interday coefficients of variation for low-, medium-, and high-quality control samples were V15% and accuracy was VF15% for all analytes (data on file). Pharmacokinetic variables were determined from the plasma concentration-time data of all evaluable patients. Scheduled time was used to present mean concentration-time profiles and to calculate the area under the curve (AUC) from time 0 to 8 h (AUC 0-8 ). Actual time (defined as the time elapsed between the initiation of infusion and blood collection) was used for standard noncompartmental pharmacokinetic analysis using WinNonLin v 5.1 (Pharsight Corp.).
Calculated pharmacokinetic variables included maximum observed plasma concentration (C max ); the time to C max (T max ); the elimination rate constant obtained from a linear regression of the natural log (ln) transformed concentration versus time data in the terminal phase (kz); the terminal elimination half-life (t 1/2 ), calculated as ln (2) 
Results
Patient characteristics. Thirty-three patients were enrolled and treated on cohorts 1 to 6 and the extension cohort (Table 1 ). Patients had a median age of 57 years and were predominantly male. All but four patients were white, and the majority of patients had an Eastern Cooperative Oncology Group performance status of 1. Eleven different tumor types were represented in the patient population; colorectal cancer was most common (15 patients, 45.5%). The average number of prior chemotherapy regimens was 2.5 among all patients. Details for prior therapies among the 15 colorectal patients are presented in Table 5 .
Dose escalation. The starting dose for this study was 30 units/m 2 (cohort 1). Because dose-limiting toxicity occurred in four patients in cycle 1 of cohort 6 (270 units/m 2 ), the maximum tolerated dose was considered to have been exceeded. Thus, an additional two patients were enrolled at the next lowest dose level (cohort 5, 210 units/m 2 ). None of the six patients at the 210 units/m 2 dose level had dose-limiting toxicity; this dose level was declared the maximum tolerated dose. Subsequently, seven patients with colorectal cancer were enrolled at 210 units/m 2 (extension cohort) to obtain additional safety and efficacy data. A total of 153 cycles of treatment were administered to 33 patients. The median number of cycles of treatment by cohort is shown in Table 1 and for the study as a whole was four cycles per patient.
Pharmacokinetics. No patients were excluded from safety or pharmacokinetic analyses. Irinotecan, SN-38, floxuridine, and 5-FU were detected in the plasma of all patients following CPX-1 treatment. Mean (arithmetic) plasma concentrations after the first infusion in patients who received 210 units/m 2 (n = 13) on day 1 are depicted in Fig. 1 . All analytes disappeared from the plasma in an apparently monophasic manner. Mean (arithmetic) pharmacokinetic variables for each dose group are shown in Supplementary Table. Pharmacokinetic variables of irinotecan and floxuridine (C max and AUC 0-last ) increased proportionately with CPX-1 doses (Supplementary Table; Fig. 2) .
For all doses, accumulation ratios (AC[C max ] and AC[AUC]) of irinotecan, SN-38, floxuridine, and 5-FU were close to 1 (data not shown). The target 1:1 molar ratio of irinotecan to floxuridine was maintained in the plasma of all patients for 8 to 12 hours. The mean molar ratios are presented in Fig. 3 .
There were no clear relationships between absolute or dosenormalized C max or AUC for any of the analytes and screening bilirubin, day 8 absolute neutrophil count or National Cancer Institute-Common Toxicity Criteria toxicity grades for diarrhea, nausea or vomiting.
Safety. One patient in cohort 6 died after the first dose of CPX-1 from dose-limiting drug -related diarrhea and vomiting, which led to dehydration and renal failure. Another patient died of progressive metastatic sarcoma unrelated to study treatment. A list of adverse events (all grades) is presented in Table 2 . Discontinuations due to adverse events occurred at 100 units/m 2 (one patient) after 20 cycles of treatment, 210 units/m 2 (one patient) after one cycle of treatment, and 270 units/m 2 (three patients) after one dose of treatment (two patients) and after three cycles (one patient). Severe adverse events that were dose related included grade 3 or 4 diarrhea (24.2%), neutropenia (12.1%), and hypokalemia (12.1%; Table 3 ). Gastrointestinal toxicities were present at all dose levels, but severity and duration increased with higher doses. Selected grade 3/4 events (diarrhea, neutropenia, nausea/vomitting, or fatigue) occurred in 9 of 24 patients with no prior irinotecan therapy and 5 of 9 patients with prior irinotecan therapy.
Serum copper levels became elevated above baseline in a dose-dependent manner. Elevations were observed in cohorts 3 (25% of patients), 4 (75%), 5 (100%), and 6 (100%), and in the Extension Cohort (100%) during cycle 1; however, there was no evidence of copper accumulation. No instances of elevated copper levels were defined as severe adverse events. One patient with biliary obstruction unrelated to CPX-1 treatment had increasing serum copper levels above normal limits (on day 1 of cycles 2, 3, and 4, respectively) that returned to normal 5 days after the implantation of a biliary stent. Response evaluation. Complete response, partial response, stable disease, and progressive disease were evaluated in 30 of 33 patients. Three patients were not evaluated because adverse events led to early removal from the study before scheduled tumor assessment could be completed. Three patients achieved a partial response, 21 patients achieved stable disease, and 6 patients had progressive disease (Table 4) . Partial response occurred in 3 of 25 (12%) subjects evaluated by Response Evaluation Criteria in Solid Tumors criteria. Disease control (complete remission, partial remission, or stable disease) was observed in 11 of 15 (73.3%) patients with colorectal cancer.
Among the 18 subjects with other tumor types, 1 partial response (non -small cell lung carcinoma) and 11 stable diseases were observed. Progression-free survival lasting >6 months was observed in six patients with colorectal cancer and one patient each with pancreatic, ovarian, and non -small cell lung carcinoma ( Table 4 ). The median progressive-free survival among colorectal cancer patients was 5.4 months. Colorectal cancer patients with prior exposure to irinotecan had no reduction in progressive-free survival compared with patients who were irinotecan-naive (Table 5) .
Discussion
In vitro findings that particular molar ratios of chemotherapy doublets may enhance antitumor efficacy, whereas other ratios may be antagonistic (4, 5, 8) , provide the basis for the concept of fixed drug ratio dosing. This novel concept has important implications for the design of combination chemotherapy regimens and suggests that control of molar ratios using drug delivery technology may be used to enhance antitumor efficacy. CPX-1 was designed according to fixed drug ratio dosing principles to present and maintain a 1:1 molar ratio of irinotecan and floxuridine, which was found to be consistently synergistic in a variety of in vitro tumor models and more active than standard irinotecan and floxuridine combination therapy in preclinical tumor models (7). This is the first report of results from a CPX-1 clinical trial. The intended 1:1 molar ratio of irinotecan and floxuridine was maintained in patient plasma for up to 12 hours, indicating that extended exposure at the predetermined, synergistic ratio was accomplished. The peak plasma levels and AUC for total irinotecan and total floxuridine were higher than what would be expected following their administration in a conventional combination treatment regimen. Colorectal  15  0  2  9  2  2  6  Pancreatic  3  0  0  2  1  0  1  Ovarian  3  0  0  3  0  0  1  Esophageal  2  0  0  0  1  1  0  Breast  2  0  0  2  0  0  0  Sarcomas  2  0  0  2 Safety-related results indicate that the recommended dose for CPX-1 use in future trials should be no higher than 210 units/ m 2 ; neutropenia and diarrhea were the dose-limiting toxicities. Adverse events were predictable, dose-related, and similar to conventional irinotecan and fluoropyrimidine treatment regimens. Previously reported prominent grade 3 or 4 adverse events following conventional irinotecan and fluoropyrimidine treatment (9 -12) include neutropenia (21-40%), diarrhea (14-44.4%), and nausea (0-16%). In this study, the incidences of grade 3 neutropenia, diarrhea, and nausea in patients treated with the recommended phase II dose (210 units/m 2 ) were 15.4%, 15.4%, and 0.0%, respectively; 23.1% of patients had grade 3 hypokalemia, which may have been secondary to vomiting and/or diarrhea.
Ten patients (at starting doses of 100 units/m 2 or above) required 11 dose reductions due to toxicities related to the study treatment. Eight of the 11 dose reductions followed severe or persistent gastrointestinal toxicities, especially diarrhea and vomiting. The dose reductions were effective and reduced the diarrhea in six of seven patients and the vomiting in one patient. The effectiveness of dose reductions in reducing the incidence and severity of adverse events strongly suggests the dose relatedness of the major gastrointestinal toxicities and neutropenia. The every 2 weeks dosing schedule allows early recognition of toxicities and prompt dose reduction when needed.
The inclusion criteria for this study required a serum total bilirubin <1.25 times the upper limit of normal; thus, it is perhaps not surprising that we did not detect a correlation between bilirubin and toxicity.
As this was a small, dose-escalating study and the existing correlation between UGT1A1 genotype and irinotecan-associated toxicity may only be relevant at high (300-350 mg/m 2 ) doses (23), UGT1A1 genotyping was not conducted in this study nor were samples collected for this purpose. Future studies of CPX-1 should include pharmacogenomic analyses.
Evaluations of tumor response and progression-free survival suggest that CPX-1 is clearly active and remains active in patients with prior exposure to irinotecan and fluoropyrimidine treatment regimens. Comparisons of first-and secondline treatments with conventional irinotecan-based treatment regimens (FOLFIRI) in colorectal cancer patients reported precipitous drops in objective response rates [31-56% (9, 11, 12) versus 4% to 35% (9, 12) , respectively]. Similarly, the rate of disease control (complete response + partial response + stable disease) also fell substantially [70-79% (9) versus 35% (12) , respectively] between the first-line and second-line treatments. CPX-1 achieved partial response in 2 of 15 (13.3%) and disease control in 11 of 15 (73.3%) patients with colorectal cancer, 12 of whom were treated in the 3rd-, 4th-, or 5th-line setting. Because fluoropyrimidines and irinotecan are not typically used for the treatment of noncolorectal solid tumors, it is interesting to note that 1 partial response and 11 stable diseases were observed among the 18 patients with other tumor types treated with CPX-1. This suggests that there is potential for antitumor activity in other tumor types.
The identification of chemotherapy doublets with efficacy dependent on particular molar ratios and the encapsulation of those doublets within a drug carrier to enable delivery of the synergistic molar ratio to the tumor target (CombiPlex Technology) may be a means of improving the efficacy of chemotherapy combinations in the future. CPX-1 is the first combination treatment regimen that has succeeded in maintaining plasma concentrations of infused drugs at a molar ratio determined to be synergistic in vitro. A phase II trial evaluating the efficacy and safety of CPX-1 in treating advanced colorectal cancer is ongoing.
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